Zhongheng Group announced that its controlling subsidiary, Chongqing Lummy Pharmaceutical Co., Ltd., has received the Drug Registration Certificate for Acetylcysteine Solution for Inhalation issued by the National Medical Products Administration. The drug specification is 3ml:0.3g, and the approval number is valid until August 3, 2031. It was developed using Zambon S.p.A.'s Fluimucil as the reference listed drug, and is indicated for respiratory diseases caused by excessive thick mucus secretions. According to Mohn Medical data, from 2024 to the end of the first quarter of 2026, the drug's sales in China's hospital terminal market were 2.339 billion yuan, 1.936 billion yuan, and 534 million yuan respectively. Lummy Pharmaceutical's total R&D investment for this drug was 2.5409 million yuan. The company stated that obtaining this registration certificate will help enrich its product line and enhance competitiveness.
Chongqing Lummy PharmaceuticalLummy Pharmaceutical received Drug Registration Certificate for its product, indicating regulatory approval and market entry.
Guangxi Wuzhou Zhongheng Group Co LtdSubsidiary obtained drug registration certificate for Acetylcysteine Solution, enriching product line and enhancing competitiveness.
